Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Phosphorylation of tau protein at threonine 231 (using full-length tau, 441 amino acids, for the numbering scheme) (p-tau(231)) occurs specifically in postmortem brain tissue of patients with Alzheimer disease (AD) and can be sensitively detected in cerebrospinal fluid (CSF). Objectives To determine to what extent CSF levels of p-tau(231) distinguish patients with AD from control subjects and from patients with other dementias, and to investigate whether p-tau(231) levels are a better diagnostic marker than levels of total tau protein (t-tau) in CSF. Design and setting Cross-sectional, multicenter, memory clinic-based studies.

What this study adds

Evidence grade: Low

This is a cross-sectional study. This cross-sectional multicenter study tested whether cerebrospinal fluid tau phosphorylated at threonine 231 could distinguish Alzheimer patients from controls and from people with other dementias, and compared it with total tau. Reported effect size: 90.2%; 80.0%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Buerger, K., Zinkowski, R., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., et al. (2002). Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Archives of neurology. https://doi.org/10.1001/archneur.59.8.1267

Vancouver

Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Archives of neurology. 2002. doi:10.1001/archneur.59.8.1267. PMID: 12164722.

BibTeX

@article{buerger2002-12164722,
  author  = {Buerger, K. and Zinkowski, R. and Teipel, S. J. and Tapiola, T. and Arai, H. and Blennow, K. and Andreasen, N. and Hofmann-Kiefer, K. and others},
  title   = {{Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231}},
  journal = {Archives of neurology},
  year    = {2002},
  doi     = {10.1001/archneur.59.8.1267},
  pmid    = {12164722},
  url     = {https://doi.org/10.1001/archneur.59.8.1267}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This cross-sectional multicenter study tested whether cerebrospinal fluid tau phosphorylated at threonine 231 could distinguish Alzheimer patients from controls and from people with other dementias, and compared it with total tau. It is a diagnostic comparison only and provides no treatment, cure, or prevention.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of neurology)
Journal's citation record 3 / 4 Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2002 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 278 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.7 citations a year over 26 year(s) since 2002
Impact for its field and year 4 / 6 Cited 10.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 27 other studies in this library
Still being cited 2 / 4 Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Harald Juergen Hampel: h-index 136 (OpenAlex, whole career)
Institution's track record 3 / 3 National Institutes of Health: institution h-index 2,723 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 12164722)
Free to read 0 / 2 Behind a paywall — scores zero
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

27 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →